Vanda Pharmaceuticals (VNDA) Capital Expenditures (2011 - 2026)

Vanda Pharmaceuticals has reported Capital Expenditures for 16 years, with the latest figure at $221000.0 in Q1 2026.

• Quarterly Capital Expenditures fell 49.31% year-over-year to $221000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $783000.0 (down 14.8% YoY) and the FY2025 annual result came in at $998000.0, up 103.67% from the prior year.
• Capital Expenditures rose to $221000.0 in Q1 2026 per VNDA's latest filing, from $102000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $436000.0 in Q1 2025 and troughed at $7000.0 in Q1 2024.
• A 5-year average of $163000.0 and a median of $161000.0 in 2024 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2024 and 2025: Capital Expenditures slumped 86.27% in 2024, then surged 6128.57% in 2025.
• Over 5 years, Capital Expenditures stood at $263000.0 in 2022, then dropped by 3.8% to $253000.0 in 2023, then slipped by 15.42% to $214000.0 in 2024, then plunged by 52.34% to $102000.0 in 2025, then soared by 116.67% to $221000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $221000.0, $102000.0, and $161000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.